Coherus BioSciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Coherus BioSciences generated cash of -$174,884,000, which is more than the previous year. Cash used in financing activities reached the amount of $69,600,000 last year. Net change in cash is therefore $39,356,000.
Cash Flow
| 2014 | -23.92M | -525K | 135.95M |
|---|---|---|---|
| 2015 | -107.99M | -6.94M | 122.68M |
| 2016 | -252.54M | -6.51M | 226.17M |
| 2017 | -200.28M | -4.41M | 206.78M |
| 2018 | -159.26M | -1.18M | 105.42M |
| 2019 | 28.35M | -12.73M | 89.37M |
| 2020 | 154.14M | -14.40M | 223.94M |
| 2021 | -37.43M | -138.41M | 51.87M |
| 2022 | -241.12M | -166.85M | 54.32M |
| 2023 | -174.88M | 144.64M | 69.6M |
CHRS Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 63.98M | 417.63M | 541.59M | 177.90M | 73.19M | 127.75M | 124.94M | 158.22M | 150.39M | 39.55M |
Operating activities | ||||||||||
Net income | -237.89M | -291.75M | -287.1M | 132.24M | 89.83M | -209.40M | -238.28M | -127.78M | -223.93M | -87.17M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 3.79M | 3.69M | 3.45M | 2.88M | 3.25M | 3.23M | 3.39M | 2.99M | 1.86M | 674K |
Stock-based compensation expense | 43.11M | 50.73M | 51.36M | 38.16M | 33.59M | 0 | 36.06M | 27.42M | 16.72M | 11.06M |
| Deferred income tax benefit | 43.11M | 50.73M | 51.36M | 38.16M | 33.59M | 0 | 36.06M | 27.42M | 16.72M | 11.06M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -150.68M | 13.05M | 34.06M | -15.21M | -141.99M | 8.27M | 1.85M | -299K | 857K | -2.13M |
Inventories | -46.73M | -47.34M | -6.25M | -36.18M | -48.18M | -5.48M | -148K | 8.25M | -1.26M | -16.15M |
Accounts payable | 23.76M | -4.54M | 874K | -9.82M | 9.89M | -534K | -4.45M | -7.63M | 19.93M | 5.26M |
Cash generated by operating activities | -174.88M | -241.12M | -37.43M | 154.14M | 28.35M | -159.26M | -200.28M | -252.54M | -107.99M | -23.92M |
Investing activities | ||||||||||
Purchases Of Investments | -19.50M | -127.38M | -182.48M | -273.84M | -20.23M | -42.86M | -74.34M | 0 | -785K | 0 |
Investments In Property Plant And Equipment | -286K | -2.03M | -1.28M | -7.05M | -12.89M | -789K | -4.57M | -6.51M | -6.16M | -2.84M |
Acquisitions Net | 845K | 0 | 1.28M | 175K | 1.65M | -700K | 0 | 0 | 0 | 2.33M |
Cash generated by investing activities | 144.64M | -166.85M | -138.41M | -14.40M | -12.73M | -1.18M | -4.41M | -6.51M | -6.94M | -525K |
Financing activities | ||||||||||
Common Stock Issued | 71.71M | 6.35M | 40.90M | 21.22M | 8.15M | 101.74M | 206.84M | 0 | 122.8M | 85.41M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -1.75M | -880K | 0 | 0 | -544K | 0 | 0 | -2K |
Repayments of term debt | 0 | 49.92M | -672K | -1.26M | 72.95M | 0 | 0 | 100M | 0 | 0 |
Cash used in financing activities | 69.6M | 54.32M | 51.87M | 223.94M | 89.37M | 105.42M | 206.78M | 226.17M | 122.68M | 135.95M |
Net Change In Cash | 39.35M | -353.64M | -123.96M | 363.69M | 104.71M | -54.56M | 1.96M | -33.27M | 7.83M | 110.83M |
Cash at end of period | 103.34M | 63.98M | 417.63M | 541.59M | 177.90M | 73.19M | 126.91M | 124.94M | 158.22M | 150.39M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |